Alaleh  Nouri net worth and biography

Alaleh Nouri Biography and Net Worth

Ms. Nouri has served as our EVP, Chief Legal Officer & Corporate Secretary since January 2022. She has also served as our Chief Compliance Officer since September 2018. She previously served as our SVP, General Counsel & Corporate Secretary from July 2018 until December 2021. Prior to joining PROCEPT BioRobotics, Ms. Nouri served as Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer at Accuray Inc., a radiation oncology company, from February 2014 to July 2018. In her more than 15-year legal career in private practice law firms and with corporations as in-house counsel, Ms. Nouri has advised on corporate, transactional, and regulatory compliance matters including corporate governance, strategic transactions, mergers and acquisitions, intellectual property portfolio management, public disclosure issues, and SEC reporting and compliance. Ms. Nouri received a J.D. from U.C. College of the Law, San Francisco (formerly U.C. Hastings College of Law) and a Bachelor of Commerce in International Business and also completed the requirements for a finance specialization from the University of British Columbia.

What is Alaleh Nouri's net worth?

The estimated net worth of Alaleh Nouri is at least $4.98 million as of June 17th, 2024. Ms. Nouri owns 52,472 shares of PROCEPT BioRobotics stock worth more than $4,981,167 as of December 3rd. This net worth approximation does not reflect any other assets that Ms. Nouri may own. Additionally, Ms. Nouri receives an annual salary of $605,840.00 as EVP at PROCEPT BioRobotics. Learn More about Alaleh Nouri's net worth.

How old is Alaleh Nouri?

Ms. Nouri is currently 45 years old. There are 5 older executives and no younger executives at PROCEPT BioRobotics. The oldest executive at PROCEPT BioRobotics is Dr. Reza Zadno Ph.D., President, CEO & Director, who is 69 years old. Learn More on Alaleh Nouri's age.

What is Alaleh Nouri's salary?

As the EVP of PROCEPT BioRobotics Co., Ms. Nouri earns $605,840.00 per year. There are 3 executives that earn more than Ms. Nouri. The highest earning executive at PROCEPT BioRobotics is Dr. Reza Zadno Ph.D., President, CEO & Director, who commands a salary of $1,130,000.00 per year. Learn More on Alaleh Nouri's salary.

How do I contact Alaleh Nouri?

The corporate mailing address for Ms. Nouri and other PROCEPT BioRobotics executives is 900 ISLAND DRIVE, REDWOOD CITY CA, 94065. PROCEPT BioRobotics can also be reached via phone at 650-232-7200 and via email at [email protected]. Learn More on Alaleh Nouri's contact information.

Has Alaleh Nouri been buying or selling shares of PROCEPT BioRobotics?

Alaleh Nouri has not been actively trading shares of PROCEPT BioRobotics during the last ninety days. Most recently, Alaleh Nouri sold 10,000 shares of the business's stock in a transaction on Monday, June 17th. The shares were sold at an average price of $62.18, for a transaction totalling $621,800.00. Following the completion of the sale, the executive vice president now directly owns 52,472 shares of the company's stock, valued at $3,262,708.96. Learn More on Alaleh Nouri's trading history.

Who are PROCEPT BioRobotics' active insiders?

PROCEPT BioRobotics' insider roster includes Antal Desai (Director), Frederic Moll (Director), Alaleh Nouri (EVP), Hisham Shiblaq (EVP, Chief Commercial Officer), Kevin Waters (EVP, CFO), and Reza Zadno (CEO). Learn More on PROCEPT BioRobotics' active insiders.

Are insiders buying or selling shares of PROCEPT BioRobotics?

In the last twelve months, insiders at the sold shares 34 times. They sold a total of 973,143 shares worth more than $70,081,453.91. The most recent insider tranaction occured on November, 27th when CEO Reza Zadno sold 26,420 shares worth more than $2,584,668.60. Insiders at PROCEPT BioRobotics own 17.4% of the company. Learn More about insider trades at PROCEPT BioRobotics.

Information on this page was last updated on 11/27/2024.

Alaleh Nouri Insider Trading History at PROCEPT BioRobotics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/17/2024Sell10,000$62.18$621,800.0052,472View SEC Filing Icon  
5/3/2024Sell30,432$62.97$1,916,303.0462,472View SEC Filing Icon  
3/18/2024Sell441$48.83$21,534.0362,472View SEC Filing Icon  
3/6/2024Sell2,749$46.67$128,295.8362,913View SEC Filing Icon  
2/9/2024Sell14,694$49.97$734,259.1847,351View SEC Filing Icon  
2/7/2024Sell5,306$49.95$265,034.7047,351View SEC Filing Icon  
1/9/2024Sell16,000$44.97$719,520.0047,351View SEC Filing Icon  
12/14/2023Sell3,204$42.95$137,611.8046,933View SEC Filing Icon  
12/6/2023Sell6,096$39.96$243,596.1646,933View SEC Filing Icon  
7/27/2023Sell7,903$40.00$316,120.0046,933View SEC Filing Icon  
12/27/2022Sell3,064$40.90$125,317.604,062View SEC Filing Icon  
12/19/2022Sell20,000$43.23$864,600.007,126View SEC Filing Icon  
12/16/2022Sell20,000$41.97$839,400.0027,126View SEC Filing Icon  
5/16/2022Sell678$35.06$23,770.6846,468View SEC Filing Icon  
See Full Table

Alaleh Nouri Buying and Selling Activity at PROCEPT BioRobotics

This chart shows Alaleh Nouri's buying and selling at PROCEPT BioRobotics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

PROCEPT BioRobotics Company Overview

PROCEPT BioRobotics logo
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Read More

Today's Range

Now: $96.48
Low: $93.28
High: $97.41

50 Day Range

MA: $84.56
Low: $66.83
High: $99.27

2 Week Range

Now: $96.48
Low: $36.52
High: $103.81

Volume

485,633 shs

Average Volume

654,822 shs

Market Capitalization

$5.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99